Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3 (CNTRACS)

5. november 2026 oppdatert av: Deanna Barch, Washington University School of Medicine

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium

In Study 3, all tasks and models from Aim 1 will be evaluated in a large community sample of online participants recruited through Prolific.

Aim 3 will establish 1) requirements for testing computational algorithms in population-based samples, 2) whether task length is optimal, and 3) whether computational parameters help predict psychopathology (hallucinations and delusions in particular) in the general population, and how these predictors may be impacted by demographic variables, such as race, ethnicity, gender, age and other social determinants of health.

Participant demographics will be matched to the U.S. Census 2023 American Community Survey (ACS) data release (updated as available). MPI MacDonald has successfully recruited large online samples for over a decade.

Specifically, researchers will recruit two samples of n=2,000 to preregister hypotheses and then n=3,000 to independently confirm those hypotheses. Multiple methods will affirm the highest quality human self-report and behavioral data for online samples.

Researchers use Prolific, which is known for high quality research participation, maintaining low levels of bots through strategies such as requiring a photo ID and a waiting period. Second, inclusion criteria will require an approval rating of 90-100% from previous researchers. Participants will complete three sessions, each limited to ~60 min to avoid burnout.

Studieoversikt

Detaljert beskrivelse

Researchers will recruit two samples of 2,000 to preregister hypotheses and then 3,000 to independently confirm those hypotheses.

Multiple methods will affirm the highest quality human self-report and behavioral data for online samples. First, researchers will use Prolific, which is known for high quality research participation, maintaining low levels of bots through strategies such as requiring a photo ID and a waiting period. Participants will complete 3 sessions, each limited to ~60 min to avoid burnout. Researchers anticipate complete data from 74% of participants, based on data completion rates in the previous online study.

General Cognitive Ability. Researchers will include standard general cognitive measures to assess the specificity of effects beyond general cognitive impairment. Specifically, researchers will include validated online measures from TestMyBrain (https://www.testmybrain.org/using-tmb/research.html; Digit Symbol Coding, Vocabulary, and Matrix Reasoning), as in our prior work in both clinical and healthy populations.

Self-Report Questionnaires: Researchers will use the Beliefs about Voices Scale which assesses attributions about the origin and power of voices, and the Yale Control Over Perceptual Experiences (COPE) scale, which evaluates the extent to which people feel they can exert control over their voices. Researchers will also use the Peters Delusion Inventory to assess the extent of delusional thinking, supplemented by the Green Paranoia Scale, which provides additional coverage of persecutory beliefs. To assess specificity, researchers will use the Patient Health Questionnaire (PHQ-9) to assess depression, the Generalized Anxiety Disorder Scale (GAD-7)78 to assess anxiety, and the Motivation and Pleasure Scale-Self-Report (MAP-SR) to assess anhedonia and motivation with the addition of additional measures of psychosis (Aberrant Salience Inventory, Schizotypal Personality Questionnaire - Brief), alcohol use (AUDIT), cannabis use (Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory), and tobacco and other substance use (World Health Organization (WHO) Alcohol, Smoking and Substance Involvement Screening Test), as researchers will not have a Stuctured Clinical Interview (SCID) for on-line participants.

Researchers will also measure daily functioning using the World Health Organization Disability Assessment Schedule (WHODAS) 2.0. Validity questions and procedures will be included. These measures will take 30 mins to complete, as researchers found in prior studies. Researchers will conduct a principal components analysis (PCA) on measures of the same construct (e.g., delusions) and perform primary analyses using the first principal component, followed by secondary analyses of specific measures False Discovery Rate (FDR) correction.

Studietype

Intervensjonell

Registrering (Antatt)

10000

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • Rekruttering
        • University of Minnesota
        • Ta kontakt med:
          • Angus MacDonald III, PhD
          • Telefonnummer: 612-624-3813
          • E-post: angus@umn.edu
        • Ta kontakt med:
    • Missouri
      • St Louis, Missouri, Forente stater, 63130
        • Rekruttering
        • Washington University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 59 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Residents of the U.S.
  • between 18-59 years of age

Exclusion Criteria:

  • Resides outside of U.S.
  • under 18 or over 59 years of age

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sine Wave Speech Task Performance
Tidsramme: 1 hour

Percentage of trials coded as speech or not vs Dprime

1 hour
Minnesota Trust Game Performance
Tidsramme: 1 hour

Percent of trusting choices depending on decision-agent and temptation vs. spite-guilt beliefs estimate

1 hour
Dynamic Trust Game Performance
Tidsramme: 1 hour

Trust indexed by mean investment versus learning rates

1 hour
Motion Perception Task Performance
Tidsramme: 1 hour

With 15 degrees of initial or changed direction vs. the probability of failing to update

1 hour
Volatility Task Performance
Tidsramme: 1 hour

Percent correct bag captures during periods of stability vs. instability - patients worse in both, but particularly impaired ininstability vs. Environmental volatility belief parameter

1 hour
Choice Probabilistic Reversal Performance Task
Tidsramme: 1 hour

Win-switch rate (higher in patients, particularly paranoid patients) vs. (prior on volatility belief updating in response tovolatility

1 hour
Kamin Blocking Task Performance
Tidsramme: 1 hour

Number of times participant predict allergy following blocked cue vs. prediction errors and learning rates

1 hour

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

30. juni 2031

Studiet fullført (Antatt)

30. juni 2031

Datoer for studieregistrering

Først innsendt

21. oktober 2026

Først innsendt som oppfylte QC-kriteriene

21. oktober 2026

Først lagt ut (Faktiske)

28. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 201904012: Study 3
  • 2R01MH084840 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Our plan is to share de-identified participant data through the National Data Archive (NDA) as required bythe National Institute of Mental Health (NIMH)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere